KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Th

KEYTRUDA is the first therapy to show a statistically significant improvement in OS as adjuvant therapy in patients with RCC at a higher risk of recurrence following nephrectomyNew OS results build on the significant disease-free survival benefit previously reported from the KEYNOTE-564 trialRAHWAY, N.J.--(BUSINESS...

Related Keywords

Japan ,Canada ,United States ,American ,Peter Dannenbaum ,Julie Cunningham ,Michael Mcardle ,Damini Chokshi ,Merck Research Laboratories ,American Society Of Clinical Oncology Annual Meeting ,Data Monitoring Committee ,European Society For Medical Oncology ,European Union ,European Society ,Medical Oncology ,Marjorie Green ,Merck Research ,Clinical Oncology Annual Meeting ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,